

Treating Multiple Myeloma in 2017 **NEW AGENTS, NEW CHALLENGES**



Suzanne Lentzsch, MD, PhD

Professor of Medicine at CUMC
College of Physicians and Surgeons
Columbia University
Director, Multiple Myeloma and Amyloidosis Service
New York Presbyterian Hospital/Columbia University Medical Center
New York, New York

Suzanne Lentzsch received her medical and doctorate degrees from Humboldt University/The Charité in Berlin, Germany. Her postdoctoral training included residency and fellowship at Humboldt University, as well as a research fellowship in the Jerome Lipper Multiple Myeloma Center (under the mentorship of Dr. Kenneth Anderson of the Dana-Farber Cancer Institute) studying the mechanism of action of thalidomide and its derivatives in multiple myeloma. Prior to joining the faculty at Columbia University, Dr. Lentzsch was Clinical Director of the Multiple Myeloma Program at the University of Pittsburgh and University of Pittsburgh Cancer Institute.

Dr. Lentzsch is an active researcher, serving as principal investigator for many clinical trials, including investigator-initiated studies for newly diagnosed and relapsed/refractory multiple myeloma and for maintenance following transplant for multiple myeloma and amyloidosis. Dr. Lentzsch also served as national principal investigator in Germany for studies evaluating the role of lenalidomide in the treatment of relapsed multiple myeloma. As Co-Chair of the Pathways Committee, Dr. Lentzsch played a major role in the development of the Multiple Myeloma Pathways at University Pittsburgh Medical Center. Additionally, her translational laboratory research work provided critical insights to understanding the mechanism of action of thalidomide and immunomodulatory drugs in multiple myeloma and bone disease.

A frequent lecturer, Dr. Lentzsch regularly presents at annual meetings of the American Society of Hematology and the American Society of Clinical Oncology, of which he is also a member. She has published over 70 original articles, editorials, and chapters—many as the lead or senior author—in such prestigious journals as the *Journal of Clinical Investigation*, *Blood*, *Cancer Research*, and *Leukemia*. In clinical practice, Dr. Lentzsch cares primarily for patients with plasma cell dyscrasias, including monoclonal gammopathy of undetermined significance (MGUS), multiple myeloma, amyloidosis, POEMS, and Waldenstrom macroglobulinemia.